COST-EFFECTIVENESS ANDCOST-UTILITY OF GENOTHERAPEUTIC DRUG NEOVASCULGEN IN TREATMENT OF CHRONIC LOWER LIMB ISCHEMIA

Медицинский совет

P. I. Shabalkin¹  S. L. Plavinsky² 

[1] Blokhin Russian Cancer ResearchCentre of the Ministry of Health;Mechnikov North-Western State Medical University of the Ministry of Health of Russia;

关键词: cost-effectiveness analysis;    cost-utility analysis;    chronic lower limb ischemia;    neovasculgen;   

DOI  :  10.21518/2079-701X-2017-14-132-135

来源: DOAJ

【 摘 要 】

Pl-VEGF165 (Neovasculgen) is a new genotherapeutic drug for treatment of chronic lower limb ischemia.  It is registered in Russia and underwent effectiveness assessment in clinical trial. Objective of this study is to report results of the economical modeling study to compare long-term effectiveness and costs of the treatment. The comparison show that the treatment with this drug allows to decrease number of amputations by 6.5 fold and increase quality adjusted length of life by 2.6 QALYs. Summary  costs were lower with new drug by 574 thousand rubles with lifelong modeling and by 353 thousand rubles in first 5 years.

【 授权许可】

Unknown